Header

BUY LIFE SCIENCE REPORTS

PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.

FEATURED REPORT

Featured Reports Icon

Global Pharmaceuticals, Biotechnology & Life Sciences

Takeda has agreed to acquire Ariad Pharmaceuticals for approximately $5.2 billion enabling it to expand its oncology portfolio to include Ariads' lead program Iclusing (ponatinib)for the treatment of ALL/AML as well as Brigatinib (AP26113) and AP32788 for the treatment of NSCLC. Ariad gained FDA approval for Iclusing in 2012 but extended its label in November 2016 to include long-term efficacy data from the PACE trial. In July 2016 the company released positive PFS survival data from the ALTA study in ALK+ NSCLC patients with Brigatinib.

FREE WHITE PAPER

Free White Paper

Factors Currently Diving Pharmaceutical Growth in the Middle East

During the last decade the pharmaceutical industry has been looking towards the emerging economies to expand its global footprint and drive future growth. This white paper focuses on the potential opportunities for investment in the Middle East, particularly with respect to Bahrain, Saudi Arabia and the United Arab Emirates.

EVENTS 2017

Events Icon

People Operations for Life Sciences

30th Jan 2017 - 1st Mar 2017